Locally Ablative Therapy for Oligoprogressive Lung and Thoracic Malignancies (OBLITERATE)

What this Trial Is About

Researchers are evaluating the clinical benefit of adding locally ablative therapies to ongoing systemic treatment for patients with oligo-progressive solid tumors, specifically non-small cell lung cancer and small cell lung cancer. This phase 2 pragmatic study aims to measure how well disease control is maintained, focusing on the time to treatment failure and continuation of systemic therapy without changes or discontinuation after local therapy. The study is conducted at a single site and sponsored by the University of California, Davis. Participants will receive locally ablative therapy, which includes stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation, in addition to their current systemic therapy. The choice of local therapy is determined by the treating radiation oncologist or interventional radiologist. The study follows participants for up to five years after the first day of ablative therapy to monitor outcomes and adverse events. During the study, participants will be assessed for disease control at three months, defined by continuation of systemic cancer therapy without change or discontinuation. Researchers will also monitor for adverse events related to local therapy, overall survival, and time to treatment failure for up to one to two years. Participants will undergo regular follow-up visits and evaluations to track their treatment response and safety throughout the study duration.

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)